BetterLife Pharma Inc.
BETRF · OTC
7/31/2025 | 4/30/2025 | 1/31/2025 | 10/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.07 | 0.18 | 0.02 | -0.04 |
| FCF Yield | -1.12% | -0.12% | -0.12% | -1.14% |
| EV / EBITDA | 0.00 | -97.74 | -20.61 | 9.38 |
| Quality | ||||
| ROIC | 10.29% | 6.50% | 12.54% | 14.49% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.35 | 0.07 | 0.03 | -0.22 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -1,109.62% | 25.76% | 86.49% | 85.82% |
| Safety | ||||
| Net Debt / EBITDA | 0.00 | -9.89 | -1.58 | 0.84 |
| Interest Coverage | 0.00 | -4.03 | 0.00 | -7.74 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |